The trading update for FY 2019 contains few surprises; a slightly better year-end cash position, which was subsequently bolstered by an $11.4m milestone payment for Chinese rights to Feraccru/Accrufer from ASK Pharm in January, offset by a c.£0.3m shortfall in revenues. Shield is in a strong financial position with a cash runway that extends well into 2021, enabling the company to conduct licensing discussions for Accrufer in the US without the pressure of needing cash. We have made min
27 Jan 2020
Shield Therapeutics - Trading update – in line, with US deal still to come
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Shield Therapeutics - Trading update – in line, with US deal still to come
Shield Therapeutics Plc (STX:LON) | 1.5 0 (-3.7%) | Mkt Cap: 11.5m
- Published:
27 Jan 2020 -
Author:
Mark Brewer | Cavendish Research -
Pages:
4
The trading update for FY 2019 contains few surprises; a slightly better year-end cash position, which was subsequently bolstered by an $11.4m milestone payment for Chinese rights to Feraccru/Accrufer from ASK Pharm in January, offset by a c.£0.3m shortfall in revenues. Shield is in a strong financial position with a cash runway that extends well into 2021, enabling the company to conduct licensing discussions for Accrufer in the US without the pressure of needing cash. We have made min